Literature DB >> 7693692

Nuclease activities of Moloney murine leukemia virus reverse transcriptase. Mutants with altered substrate specificities.

S W Blain1, S P Goff.   

Abstract

RNases H are traditionally thought to degrade RNA only in RNA-DNA hybrid form. We found that the wild-type Moloney murine leukemia virus (M-MuLV) reverse transcriptase (RT) was capable of degrading RNA in RNA-RNA duplexes as well as in RNA-DNA hybrids, as assayed by in situ gel techniques. Escherichia coli RNase H does not degrade the RNA-RNA duplex in this assay, while E. coli RNase III, a double-strand-specific ribonuclease, does. The apparent specific activity of M-MuLV RT on RNA-RNA duplexes is similar to that on RNA-DNA hybrids. Neither the DNA polymerase domain nor the RNase H domain of RT expressed individually exhibited this RNA-RNA activity. We have generated a series of mutations in the RNase H domain of M-MuLV RT, expressed the mutant enzymes in E. coli, and assayed these mutants for various activities. All RTs were as active as the wild type in the oligo(dT):poly(rA) DNA polymerase assay, and many retained both nuclease activities. Two enzymes with mutations at the carboxyl terminus of the RNase H domain retained RNA-DNA activity, but not RNA-RNA activity. Another mutant enzyme showed the opposite phenotype, retaining RNA-RNA, but not RNA-DNA, nuclease activity. Thus, we were able to genetically separate the two activities. These results may be helpful in defining enzyme-substrate interactions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693692

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  Structural determinants of murine leukemia virus reverse transcriptase that affect the frequency of template switching.

Authors:  E S Svarovskaia; K A Delviks; C K Hwang; V K Pathak
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  Expression of Moloney murine leukemia virus RNase H rescues the growth defect of an Escherichia coli mutant.

Authors:  A G Campbell
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  NMR structure of the chimeric hybrid duplex r(gcaguggc).r(gcca)d(CTGC) comprising the tRNA-DNA junction formed during initiation of HIV-1 reverse transcription.

Authors:  T Szyperski; M Götte; M Billeter; E Perola; L Cellai; H Heumann; K Wüthrich
Journal:  J Biomol NMR       Date:  1999-04       Impact factor: 2.835

4.  Development of an in vivo assay to identify structural determinants in murine leukemia virus reverse transcriptase important for fidelity.

Authors:  E K Halvas; E S Svarovskaia; V K Pathak
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

5.  Effects on DNA synthesis and translocation caused by mutations in the RNase H domain of Moloney murine leukemia virus reverse transcriptase.

Authors:  S W Blain; S P Goff
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

6.  Reversion of a Moloney murine leukemia virus RNase H mutant at a second site restores enzyme function and infectivity.

Authors:  S W Blain; W A Hendrickson; S P Goff
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

7.  Redesignation of the RNase D activity associated with retroviral reverse transcriptase as RNase H.

Authors:  Z Hostomsky; S H Hughes; S P Goff; S F Le Grice
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  An unusual mechanism of self-primed reverse transcription requires the RNase H domain of reverse transcriptase to cleave an RNA duplex.

Authors:  H L Levin
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

9.  Replication defect of moloney murine leukemia virus with a mutant reverse transcriptase that can incorporate ribonucleotides and deoxyribonucleotides.

Authors:  G Gao; S P Goff
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  Mutational analysis of the reverse transcriptase and ribonuclease H domains of the human foamy virus.

Authors:  D Kögel; M Aboud; R M Flügel
Journal:  Nucleic Acids Res       Date:  1995-07-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.